Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma, fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy exists
• •* Must have tissue available from tumor biopsy to grow tumor cells ex vivo
• •* Must have failed standard therapy with both a platinum agent (cisplatin or carboplatin) and paclitaxel
• •Site of disease must be less than 5 cm in greatest diameter
• •Evaluable disease by CT scan, physical exam, or laparoscopy
• •No significant peritoneal fibrosis either from disease or prior surgery
• •* Surgical lysis of adhesions allowed
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC greater than 2,000/mm3
• •Absolute neutrophil count at least 1,000/mm3
• •Platelet count at least 50,000/mm3
• •Hemoglobin at least 8.5 g/dL (without transfusion)
• •Hepatic:
• •Bilirubin no greater than 2.0 mg/dL
• •SGOT or SGPT no greater than 4 times upper limit of normal (ULN)
• •Alkaline phosphatase no greater than 4 times ULN
• •Hepatitis B surface antigen test required prior to study if transaminases greater than 2.0 times ULN
• •No hepatitis B surface antigen
• •Amylase normal
• •PT and PTT normal
• •Renal:
• •Creatinine no greater than 2.0 mg/dL OR
• •Creatinine clearance at least 50 mL/min
• •Cardiovascular:
• •No cardiac dysfunction by history and exam
• •No ischemic heart disease that may be considered anesthetic or operative risk
• •Pulmonary:
• •No lung disease that may be considered anesthetic or operative risk
• •Other:
• •HIV negative
• •Not pregnant or nursing
• •No acute viral, bacterial, or fungal infection requiring medication within 14 days prior to study
• •No patient with greater than 2 L of ascites at the time of intraperitoneal infusion
• •No underlying condition that would preclude compliance
• •No allergies to study reagent
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •No concurrent chemotherapy
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •Not specified
• •Surgery:
• •See Disease Characteristics
• •Other:
• •No concurrent high dose vitamin regimens